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ABSTRACT 
APPROACHES IN THE TREATMENT OF PARKINSON'S DISEASE: A FOCUS ON 
STEM CELL-BASED THERAPIES 
Tareq Al-maqtari 
March 1,2012 
Parkinson's disease (PD) is a hypokinetic movement disorder resulting from the 
progressive neurodegeneration of the dopaminergic nigrostriatal system in the brain and 
the resulting imbalance between dopamine and acetylcholine in the basal ganglia motor 
circuitry. Although drug-based therapy approaches have shown dramatic symptomatic 
improvement in patients, they do not halt the progressive nature of the disease and their 
long-term use is associated with distressing adverse side effects. Consequently, several 
studies have aimed at discovering effective non-pharmacological strategies to reduce or 
to eliminate the need for drugs and possibly to halt or to reverse the neurodegenerative 
process in PD. Surgical deep brain stimulation, neurotrophic factor delivery, gene therapy 
and cell replacement therapy are potential candidates. Here, we review the latest 
advancements in the aforementioned therapeutic strategies paying special attention to 
regenerative stem cell- (SC)-based approaches in combating PD. Although intra-
cerebrally transplanted SC-derived cells can replace degenerated neurons in PD and 
simultaneously secrete neurotrophic factors that can partly protect the viable ones, 
potential tumorigenicity and low survivability of these cells hinder the advancement of 
this novel therapeutic approach. Hence, more investigations are needed to resolve the 
associated safety and efficacy concerns in order to make SC-based therapy a feasible 
therapy for PD patients. 
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Parkinson's Disease 
CHAPTER I 
INTRODUCTION 
Parkinson's disease (PD) is a progressive degenerative disorder of the central nervous 
system that primarily affects the elderly. It is named after the English· doctor, James 
Parkinson, who first described the disease in 1817. PD affects around 18 per 100,000 
person-years and has a higher prevalence in males (Corti et aI., 2011). The degenerative 
symptoms of PD arise primarily from the progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) of the midbrain (see figure 1) and result in motor 
system abnormalities such as bradykinesia, tremors, muscular rigidity and postural 
instability (Halliday and McCann, 2010). 
PD-related symptoms progress in a time-dependent manner such that the pre-
symptomatic stages are associated with smell and autonomic dysfunctions, the 
symptomatic stages with motor abnormalities, and the final stages with dementia in many 
cases. The slow progression of the disease results from neurodegeneration afflicting the 
olfactory bulb and the medulla oblongata in pre-symptomatic stages 1 and 2, the SNpc in 
stages 3 and 4, and the telencephalic cortex in stages 5 and 6 (Braak et aI., 2002). The 
fact that PD patients also experience non-motor psychiatric, cognitive and autonomic 
symptoms indicates that non-dopaminergic neurons also become affected in the course of 
the disease (Chaudhuri et aI., 2006). 
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Figure 1. Dopaminergic neurons or the suhstantia nigra compacta (SNc), which extend to the striatum .. 
degenerate in Parkinson's disease. (Source of the piClUn.:: Longo DL, Fauci AS, Kasper DL. Hauser SL. 
Jameson J L. Loscalm J: Harrison's Principals or I nlernal Medicinc. 18'h Edition. 
www .acces<.medlcine.com) 
Protein Aggregation and PD pathophysiology 
Although the exact cause of PD remams largely unknown; inflammation, oxidative 
stress, mitochondrial damage, dysfunction of the ubiquitin proteosome degradation 
system, and altered activity of certain kinases, all appear to promote the formation of 
Lewy bodies, intracellular proteinaceous aggregates observed m PD-affected 
dopaminergic neurons, eventually resulting in neuronal cell death (McNaught et aI. , 
2003; Schulz, 2008). The components of Lewy bodies include alpha-synuclein (SNCA)-
the major fibrillary component of these bodies, neurofilament proteins and ubiquitin 
(Corti et aI., 2011). SNCA is abundantly expressed in the brain especially at presynaptic 
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nerve terminals where it may modulate dopaminergic transmission (Li et aI., 2004). 
Mutations in SNCA increase the tendency of the corresponding protein to aggregate into 
Lewy bodies, resulting in neuronal cell death (Goedert et aI., 1998). Whereas the exact 
mechanistic relationship between Lewy bodies and cell death remains obscure, there is 
some evidence that SNCA oligomers, not the fibrillary form, are responsible for neuronal 
cell death (Goldberg and Lansbury, 2000), suggesting a possible detoxification role for 
the Lewy bodies. These conclusions are supported by observations that Lewy bodies exist 
in the surviving neurons of PD patients as well as in the neurons of healthy individuals 
(Parkkinen et aI., 2005). Further, some studies postulate that dopamine plays a role in 
stabilizing SNCA oligomers; promoting the selective degeneration of dopaminergic 
neurons (Lansbury et aI., 2001). Although the exact role of SNCA in PD remains largely 
unknown, the general consensus is that its accumulation disrupts multiple cellular events 
and induces distinctive neurodegeneration (Litvan et aI., 2007b). 
Genetic causes of PD 
Most cases of PD are spontaneous or idiopathic in nature with a small percentage 
resulting from specific genetic mutations (de Lau and Breteler, 2006). In general, familial 
PD patients exhibits the same clinical picture as sporadic PD patients except for an earlier 
onset in many but not all inherited cases (Gasser, 2007). Genes coding for SNCA 
(SNCA), leucine rich repeat kinase 2 (LRRK2) and ubiquitin carboxyl-terminal hydrolase 
Ll (UCH-Ll) are involved in autosomal dominant forms, whereas genes coding for 
parkin (PRKN) , PTEN-induced putative kinase 1 (PlNKl), ATPase type 13A2 
(ATP13A2), and the Parkinson's disease associated protein DJ-l (PRKN7) are involved in 
autosomal recessive forms of PD (Schulz, 2008). The identification of these genes has 
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shed light on the molecular pathophysiology of the disease, but the precise role of these 
genes in healthy and PD patients remains largely unknown (Hatano et aI., 2009). Most of 
these genes appear to interact with one another and play roles in mitochondrial function, 
oxidative stress and/or protein ubiquitination. 
Identification of point mutations and genomic multiplications in SNCA, the first PD gene 
to be mapped, led to the discovery that the encoded protein is the main component of 
Lewy bodies, the pathological hallmark in familial and sporadic PD (Corti et aI., 2011). 
SNCA is a small protein (140 KDa) whose overexpression, through duplication and 
triplication of the encoding gene, is associated with neuronal toxicity in humans and in 
animal models, indicating that gain-of-function mutations also contribute to the 
pathogenesis of PD (Martin et aI., 2011). Recent studies demonstrate that SNCA 
promotes assembly of soluble N-ethylmaleimide sensitive factor attachment protein 
receptor complexes (that are required for fusion of vesicles to the presynaptic neuronal 
membrane), suggesting a potential role of SNCA in dopaminergic transmission (Martin et 
aI.,2011). 
LRRK2 is the other gene most commonly associated with late-onset, autosomal dominant 
form of familial PD (Gasser, 2007). Like SCNA, the exact function of LRRK2 in the 
brain remains obscure. However, LRRK2 kinase activity is associated with cellular 
toxicity and neuronal cell death and the gain-of-function point mutations of LRRK2, 
observed in familial and sporadic PD, result in enhanced kinase activity (Cookson et aI., 
2007). Mutations in LRRK2 are not necessarily associated with the formation of Lewy 
bodies (Funayama et aI., 2002). Nonetheless, they constitute the major genetic mutations 
associated with familial PD. 
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Loss-of-function mutations in PRKN were first discovered among the Japanese to cause 
autosomal recessive, early-onset familial PD with no Lewy body accumulation (Hatano et 
aI., 2009). PRKN is a protein localized primarily in the cytoplasm that tags proteins for 
proteosomal degradation. As an E3 ubiquitin ligase in the ubiquitin-protesome 
degradation system, mutations in PRKN are postulated to impair its ability to interact 
with E2 ubiquitinating enzymes, leading to the buildup of nonubiquitinated substrates 
that leads eventually to neuronal cell death (Dawson and Dawson, 2010; Shimura et aI., 
2000). Like PRKN, PINK1 and DJ-1 are also responsible for autosomal recessive forms 
of PD. These three genes are involved in pathways that regulate mitochondrial 
morphology and function, corroborating the role of mitochondrial damage in the etiology 
of PD (Corti et aI., 2011). It has been proposed that PINK1 is a protein located in the 
mitochondria that interacts with DJ-1 to modulate the activity of PRKN in protein 
ubiquitination (Xiong et aI., 2009). Hence, loss-of-function mutations in PINK1 hinder 
the role of the encoded protein in a mitochondrial quality-control pathway, resulting in 
neuronal dysfunction and death (Martin et aI., 2011). On the other hand, DJ-1 is thought 
to maintain the integrity and functionality of mitochndria against oxidative stress 
(Thomas et aI., 2011). DJ -1 undergoes a modification at a conserved cystein residue 
before relocating into the mitochondria where it exerts its protective effect (Canet-Aviles 
et aI., 2004). However, further investigations are needed to confirm the precise role of 
PINK1 and DJ-1 in patients and healthy individuals. 
UCH-L1 is expressed abundantly in the brain and appears to act as a deubiquitinating 
enzyme and has been observed as a component of Lewy bodies in sporadic PD (Larsen et 
aI., 1998; Lowe et aI., 1990). There is very little known about the physiological and 
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pathological roles of ATP l3A2 although it appears to playa role in protein degradation 
via lysosomal pathways (Hatano et aI., 2009). Other PD-related genes include Htr serine 
peptidase 2 (HTRA2/0Ml) that possibly plays a role in protecting neurons from oxidative 
stress in a common pathway that involves PlNKl, PRKN (Tain et aI., 2009), 
phospholipase A2 group VI (PLA2G6) and F-box protein 7 (FBX07) (Lesage and Brice, 
2009). Taken together, whereas substantial progress has been made in the identification 
of genes related to PD, relatively little is known regarding the function of these genes in 
the etiology of the disease. Therefore, further investigations are needed to help elucidate 
their role to pave the road for targeted therapies in the treatment of PD. 
Dopamine and PD 
Dopamine and acetylcholine are central components of the movement-regulating 
neuronal circuits in the basal ganglia. Onset of familial and sporadic PD is characterized 
by the death of dopaminergic neurons of the SNpc, resulting in diminished dopamine 
release into the striatum which in turn leads to the classical motor disturbances observed 
in PD. Therefore, restoring dopamine/acetylcholine balance is the primary goal of 
pharmacotherapy aimed at mitigating symptoms associated with PD. 
Pharmacological approaches in the treatment of PD 
Levo-dopa, the precursor of dopamine, is a highly effective drug in the treatment of PD, 
especially when used in the early stages. It crosses the blood-brain barrier, which 
separates systemic circulation from the brain extracellular fluid, and restores dopamine 
levels in the striatum of PD patients. However, levo-dopa is metabolized by the 
peripheral nervous system resulting in distressing side effects such as dyskinesia, shorter 
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duration of drug-induced benefit (wearing off), and on-off pulsatile response fluctuations 
associated with long-term levo-dopa. Peripheral decarboxylase inhibitors (carbidopa, 
benserazide) are usually administered with levo-dopa to decrease its peripheral 
metabolism and enhance its activity in the central nervous system (Olanow et aI., 2006). 
Nonetheless, levo-dopa does not address the cause of PD and does not improve the non-
motor autonomic, affective and cognitive symptoms accompanying the disease. 
Other anti-PD drugs include dopaminergic receptor agonists, inhibitors of dopamine 
degradation, and anticholinergic agents. Dopaminergic receptor agonists act by direct 
stimulation of the dopaminergic receptors in the brain and include bromocriptine, 
pergolide, pramipexole and ropinirole. If used before L-dopa, they delay the onset of drug 
therapy-induced dyskinesia but at the expense of poorer management of motor symptoms 
(Clarke and Guttman, 2002). Inhibitors of dopamine metabolism prolong the efficacy of 
levo-dopa and include monoamine oxidase B inhibitors (selegiline, rasagiline) and 
catechol-o-methyltransferase inhibitors (tolcapone, entacapone). Monoamine oxidase B 
inhibitors undergo extensive first-pass metabolism, resulting in production of active 
amphetamine metabolites and low bioavailability, and are associated with insomnia, 
psychosis and cardiac arrhythmias (Poston and Waters, 2007). Catechol-o-
methyltransferase inhibitors can be added to the conventional levo-dopa/carbidopa 
combination to provide better symptomatic control in PD patients (Sethi et aI., 2009). 
Anticholinergic agents are less effective and act by blocking the muscarinic receptors to 
restore the functional balance between dopamine and acetylcholine in the basal ganglia 
(Mestre and Ferreira, 2010). They may be used alone or in combination with levo-dopa to 
improve the motor functions in PD patients. However, They may induce 
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neuropsychiatric, cognitive and other typical anticholinergic side effects (dry mouth, 
blurred vision, urinary retention, and cardiotoxicity) (Katzenschlager et aI., 2003). 
All the aforementioned anti-PD drugs are accompanied with adverse side effects and do 
not halt or reverse disease progression (Toulouse and Sullivan, 2008). More importantly, 
the effectiveness of these drugs depends greatly on the functionality of the remaining 
dopaminergic neurons to synthesize and secrete dopamine which decreases as the 
degeneration worsens. In addition, a recent study showed that the total cost of PD were 
approximately 8640 Euros per patient over a 6-month period. Anti-PD drugs were the 
major component of costs paid by the health insurance companies (39.6%), constituting a 
quarter of PD direct costs (Winter et aI., 2010). Another report estimated the annual cost 
of prescribed drugs post-treatment initiation at $3854. However, - 67% of patients do not 
adhere well to drug therapy due to the multiple dosing and regimen complexity of anti-
PD drugs leading to disease worsening and - $3451 annual increase in all-cause PD 
associated costs (Davis et aI., 2010). Hence, there is an urgent need for new and 
improved therapies that can replace or reduce the need for anti-PD medications in the 
treatment of PD. 
As current pharmacotherapy does not prevent the progression of PD, it is imperative that 
new treatment strategies be developed that can replenish lost dopaminergic neurons 
and/or prevent the loss of these neurons in affected individuals. Development of drugs 
that enhance neurogenesis and/or help mobilize newly-formed neurons to the affected 
brain areas is an interesting approach for the treatment of PD that needs to be further 
investigated. For instance, serotonin stimulates brain-derived neurotrophic factor (a 
secreted protein that enhances neurons maturation and survival) expression and the 
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administration of selective serotonin reuptake inhibitors enhances the activity of brain-
derived neurotrophic factor and alleviates symptoms of Huntington's disease in a mouse 
model (Duan et al., 2008). Similarly, dopaminergic receptor D2 and adrenergic receptor 
alfa-2 agonists and antagonists, respectively, have been shown to promote neurogenesis 
in murine animals (Borta and Hoglinger, 2007; Rizk et aI., 2006). Both the excitatory 
neurotransmitter glutamate and the inhibitory neurotransmitter gamma-aminobutyric acid 
(GABA) play roles in neurogeneration and, hence, may be potential targets for 
pharmacological intervention to treat neurodegenerative diseases (Hagg, 2009). Further, 
nicotine is thought to enhance sub ventricular zone neurogenesis through the activation of 
cholinergic nicotinic receptors, resulting in downstream increase of fibroblast growth 
factor 2 (FGF-2). Kainic acid, however, appears to enhance FGF-2-mediated 
neurogenesis through a cannabinoid receptor-l dependent manner (Aguado et aI., 2007). 
Advantages of these pharmacological approaches include: (i) availability of many 
candidate drugs with established safety profiles, (ii) ease of administration, and (iii) the 
feasibility of withdrawing drugs in case adverse side effects and/or complications occur. 
However, several impediments still exist including: (i) possible failure of these drugs due 
to severe degeneration in their respective sites of action and/or due to down-regulation of 
their receptors, (ii) potential side effects and/or toxicities, and (iii) lack of knowledge 
regarding the precise site of action, the potentially-affected tissues and exact mechanism 
of action of the drugs (Hagg, 2009). Obviously, generating small molecules that can 
directly stimulate receptors of neurotrophic factors is likely to prove valuable. 
Gene therapy, neurotrophic factor treatment and cell replacement therapy are all 
currently being developed as potential options in combating this degenerative disorder. A 
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combinatorial strategy may be the most effective approach for replacing the 
dopaminergic neurons that are lost during the course of the disease and protecting the 
remaining neurons. In the following chapters, we discuss the current status of non-
pharmacological approaches with a special focus on stem cell (SC) based cell 
replacement therapy in the treatment of PD. 
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CHAPTER II 
ALTERNATIVE THERAPEUTIC APPROACHES IN PD 
The failure of pharmacological agents to halt the progressive neurodegeneration in PD 
has resulted in the development of alternative therapeutic approaches including brain 
stimulation, neurotrophic factor-based therapies, gene therapy, fetal midbrain graft 
transplantation, and SC-based therapy. 
I. Deep brain stimulation 
Deep brain stimulation is used in the advanced stages of PD and involves the surgical 
implantation of a brain pacemaker usually in the subthalamic nucleus or the globus 
pallidus pars interna. The pacemaker sends high frequency electrical impulses resulting in 
the mitigation of the symptoms of PD, which in turn helps in reducing the dose of anti-
PD drugs. Deep brain stimulation is implemented only in advanced cases when drug-
treatment is no longer effective or is accompanied by distressing side effects. Since its 
approval by the food and drug administration in 2002, deep brain stimulation has 
improved motor symptoms (bradykinesia, rigidity, tremors and dyskinesia) in many PD 
patients for up to 5 years and appears to induce better results in L-dopa-responsive 
patients with intact cognitive abilities (Bronstein et aI., 2011). However, since deep brain 
stimulation requires a major surgery in the brain, and does not address or reverse the 
cause of neurodegeneration, it is viewed as a less attractive approach in the treatment of 
PD. 
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II. Neurotrophic factor-based therapy 
Neurotrophic factors are secreted proteins that play a key role in the induction, 
specification, maturation, survival and protection of neurons (Sullivan and Toulouse, 
2011). Therefore, lack of neurotrophic factors has been hypothesized to contribute to the 
pathophysiology of PD (Connor and Dragunow, 1998). Neurotrophic factors that act on 
dopaminergic neurons include: members of the classic neurotrophin family such as brain-
derived neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF) family 
such as GDNF and neurturin, and novel neurotrophic factors such as conserved dopamine 
neurotrophic factor and mesencephalic astrocyte-derived neurotrophic factor. Of all the 
identified neurotrophic factors, GDNF and neurturin have shown the most encouraging 
results as therapeutic targets for degenerative disorders. Whereas the advantage of 
delivering a combination of neurotrophic factors using single gene-delivery approach is 
enticing, albeit controversial (Sun et ai., 2005; Zurn et ai., 1996), delivering these factors 
into the brains of patients is problematic. This is because the neurotrophic factors cannot 
pass the blood brain barrier and undergo rapid metabolism, raising the need for long-
lasting local delivery system. In addition to direct intracerebral infusion, transplantation 
of neurotrophic factor-expressing cells and in vivo gene therapy have all been 
implemented to deliver sufficient quantities of neurotrophic factors to the brain 
(Rangasamy et ai., 2010). 
Glial cell line-derived neurotrophic factor (GDNF) 
GDNF is a member of the GDNF family of neurotrophic factors that also include 
neurturin, artemin and persephin. The GDNF family of proteins bind to 
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glycosylphosphatidylinositol (GPI)-linked receptors called GDNF family receptors alpha 
1,2 ,3 and4 (GFRul,2 ,3 and-4), and activate a transmembranous tyrosine kinase, re-
arranged during transfection (RET), to induce downstream signaling that includes 
mitogen activated protein kinase (MAPK) and phospholipase Cy pathways (Sariola and 
Saarma, 2003). GDNF has been isolated from glial cells and was confirmed to exert 
neuroprotective effect on cultured dopaminergic neurons (Lin et aI., 1993). Furthermore, 
GDNF has been shown to induce tyrosine hydroxylase, the rate-limiting enzyme in 
dopamine synthesis, in fetal human and rat cerebral cortical cultures (Theofilopoulos et 
aI.,2001). 
In vivo studies have demonstrated the ability of intracerebrally-injected GDNF to protect 
dopaminergic neurons and induce functional improvement in murine and primate models 
of PD (Gash et aI., 1996; Tomac et aI., 1995). To inject neurotrophic factors, a 
stereotactic surgery is performed after determining the precise delivery region in the brain 
by co-localization studies using positron emission tomography scanning of dopamine 
uptake and magnetic resonance imaging. Although open-label clinical studies showed 
positive results (Gill et aI., 2003; Slevin et aI., 2007), double-blind randomized clinical 
trials using intraventricular and intraputaminal infusion of recombinant GDNF showed 
mild or no therapeutic benefit and were even accompanied with distressing side effects 
such as nausea, vomiting, anorexia and paresthesias (Lang et aI., 2006; Nutt et aI., 2003). 
These disappointing results led the sponsor (Amgen) to terminate all GDNF clinical 
studies. The discrepancy between open-label and double-blind trials may be attributed to 
open-label study-associated subjective evaluation bias, the exact site of injection, 
variability of graft composition (the proportion of dopaminergic, serotonergic, 
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GABAergic, substance P-containing neurons and glial cells), tissue preparation 
(suspension, solid tissue or strands) and/or statistical analyses. 
Alternative methods of delivering GDNF include ex vivo transfected cell therapy and in 
vivo gene therapy. The ex vivo transfected cell therapy approach is based on implanting 
GDNF-expressing cells into the SNpc or striatum. Encapsulated GDNF-producing cell 
lines have shown therapeutic results in animal models of PD (Yasuhara et aI., 2005). 
Furthermore, transplantation of several primary cell lines, genetically modified to express 
GDNF, have shown beneficial effects during in vivo animal studies (Behrstock et aI., 
2006; Ericson et aI., 2005). To our knowledge, no clinical trials have been conducted for 
GDNF-secreting cells. On the other hand, in vivo gene delivery is aimed at delivering 
GDNF continuously to the nigrostriatal system using viral vectors. Virus-based methods 
of delivering GDNF circumvents the rapid metabolism of GDNF and have been shown to 
induce behavioral recovery in 6-hydroxydopamine- (6-0HDA)-lesioned rats (Bilang-
Bleuel et aI., 1997; Mandel et aI., 1997). Although some success has been achieved in 
animal models, clinical trials have not been warranted due to ethical and technical 
concerns. 
Neurturin 
Neurturin belongs to the GDNF family of ligands and was identified as a survival-
enhancing factor for sympathetic neurons (Kotzbauer et aI., 1996). It shares 42% 
homology with GDNF and is part of a signaling pathway that involves RET -tyrosine 
autophosphorylation and activation of MAPK and phosphatidylinositol 3-kinase (PI3K) 
(Creedon et aI., 1997). Neurturin is expressed in the ventral midbrain and striatum and 
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has been shown to enhance the survival of dopaminergic neurons in a fashion similar to 
GDNF (Horger et aI., 1998). 
Studies have shown the ability of cerebrally-injected neurturin to induce functional 
recovery in 6-0HDA-Iesioned rats (Oiwa et aI., 2002) and I-methyl-4-phenyl-l,2,3,6-
tetrahydropyridine- (MPTP)-lesioned monkeys (Grondin et aI., 2008). In addition, ex vivo 
transfected cell therapy, as another approach for neurturin delivery into the nigrostriatal 
system, via the intracerebral implantation of genetically-modified cells has been 
exploited. Neural stem cells (NSCs) overexpressing neurturin showed neuroprotective 
effects and induced functional recovery in a rat model of PD (Liu et aI., 2007). Another 
approach to deliver neurturin continuously to the brain is in vivo viral-based neurturin 
gene delivery to the SNpc and has shown efficacy in protecting dopaminergic neurons of 
the nigrostriatal pathway in rats (Fjord-Larsen et aI., 2005) and monkeys (Kordower et 
aI.,2006). 
In an open-label clinical trial, CEREI20, an experimental adeno-associated VIruS 2 
(AAV2) vector carrying the gene for human neurturin and developed by Cere gene Inc., 
was bilaterally injected into the putamen of 12 patients (Marks et aI., 2008). No serious 
side effects were reported and improvement in off-medication Unified Parkinson's 
Disease Rating Scale (UPDRS) was observed. UPDRS is a common scoring system first 
developed in the 1980s that comprehensively examines the mood, mental state, daily 
activities, and motor symptoms in patients in order to quantify the severity of PD. Each 
question used in UPDRS, that has to be answered by the patient or by the caregiver, 
assesses the severity of a PD symptom on a scale of 0-4 (0 = normal, 1= slight, 2 = mild, 
3 = moderate, 4 = severe). A newer verSIOn of UPDRS, revised by the movement 
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disorder society, rates 65 items with a 0-4 value whereas the older version rates 55 items, 
47 with a 0-4 value and 7 items with yes or no (Goetz et aI., 2008). 
Following the CERE120-open label study, a double-blind randomized multicenter trial of 
58 patients showed failure of bilateral intraputaminal injection of CERE-120 to reach the 
primary endpoint with no therapeutic differences observed between controls and treated 
PD patients at 12 months post-therapy. However, a longer-term follow-up study on a 
subgroup of the same patients revealed a modest clinical improvement at 18 months post-
therapy. Additionally, subsequent post-mortem investigation on 2 patients, who died for 
reasons unrelated to the treatment, revealed that neurturin expression was limited to the 
putamen, indicating limited retrograde transport of neurturin through the degenerated 
nigrostriatal neurons to the SNpc. To circumvent the deficiency in retrograde transport, 
Ceregene has decided to initiate another CERE-120-based phase II trial that targets both 
the putamen and the SNpc (Marks et aI., 2010). The results of the trial have not been 
revealed at the time of writing. 
Brain-derived neurotrophic factor 
Brain-derived neurotrophic factor is widely expressed in the brain and plays a critical role 
in the axonal growth and neuronal regeneration (Lykissas et aI., 2007). Whereas several 
studies report brain-derived neurotrophic factor to have neuroprotective effects in 
chemically-induced nigrostriatal dopaminergic neuron injury; it also supports neuronal 
maturation under homeostatic conditions (Baker et aI., 2005). It acts by interacting with 
two receptors abundantly expressed in the nigrostriatal system, tyrosine kinase B (TrkB) 
and p75 neurotrophin receptor (p75NTR) (Yan et aI., 1997). 
16 
Ex vivo and in vivo strategies, for delivering brain-derived neurotrophic factor into the 
brain, have been investigated. Astrocytes and fibroblasts, genetically modified to express 
brain-derived neurotrophic factor and injected intrastriatally in a rat model of PD, 
resulted in functional motor improvement (Levivier et al., 1995; Yoshimoto et al., 1995). 
However, in vivo gene transfer of brain-derived neurotrophic factor gene into the SNpc of 
parkinsonian rats failed to exhibit neuroprotective properties (Klein et al., 1999; Sun et 
al., 200S), indicating the insufficiency of brain-derived neurotrophic factor single-gene 
delivery. Moreover, supraphysiological amounts of brain-derived neurotrophic factor 
could be associated with deleterious effect on neuronal circuits, impaired learning, and 
increased susceptibility to seizures (Croll et al., 1999). The mixed results observed with 
brain-derived neurotrophic factor therapy were not convincing enough to warrant 
conducting clinical studies. Besides GDNF, neurturin and brain-derived neurotrophic 
factor, the utility of several other growth factors, including vascular endothelial growth 
factor, pigment epithelium-derived factor, growth/differentiation factor S, neurotrophin-3, 
neurotrophin-4/S, conserved dopamine neurotrophic factor and mesencephalic astrocyte-
derived neurotrophic factor, in the treatment of PD has been and/or is being explored 
(Falk et al., 2010; Lindholm et al., 2007; Sullivan et al., 1997; Ventimiglia et al., 1995; 
Voutilainen et al., 2009). 
Lately, the focus is shifting to implanting genetically-engineered neurotrophic factor-
expressing SCs to replace dead dopaminergic neurons and simultaneously protect the 
remaining neurons in patients. Another potentially-effective approach is the use of small 
molecules to enhance the activity of endogenous neurotrophic factors. For instance, it 
was demonstrated that intracerebral infusion of peroxovanadium, an inhibitor of protein 
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tyrosine phosphatases, can protect neurons in the SNpc of 6-0HDA-Iesioned rats by 
enhancing the activity of endogenous neurotrophic factors on their respective tyrosine 
kinase-linked receptors (Yang et aI., 2007). Creating small molecules that could directly 
activate neurotrophic factor receptors would be of great interest as well. 
III. Gene therapy 
Gene therapy in PD offers the advantage of delivering therapeutic genes into specific loci 
in the brain using a one-time stereotaxic surgical procedure, resulting in robust long-term 
gene expression. Gene therapy primarily aims at achieving one or more of the following 
three goals. The first goal is to boost the production of dopamine into the striatum by 
over-expressing dopamine synthesizing enzymes such as tyrosine hydroxylase (Zhang et 
aI., 2004) and aromatic L-amino acid decarboxylase (AADC) (Li et al., 2006). The 
second goal is to protect the remaining dopaminergic neurons in the basal ganglia by 
utilizing genes of neurotrophic factors such as GDNF (Akerud et aI., 2001) and neurturin 
(Fjord-Larsen et aI., 2005). The third goal is to modulate basal ganglia circuits through 
the introduction of glutamic acid decarboxylase (GAD), the enzyme that converts 
glutamic acid into inhibitory GABA, in the subthalamic nucleus (Emborg et aI., 2007). 
AA V and lentiviruses (LV) are typically used to introduce the genes of interest into the 
striatum, SNpc or subthalamic nucleus cells of PD patients, using direct stereotaxic 
injections. AA V vectors are preferred in PD clinical trials due to their low 
immunogenicity and ability to induce potent, long-term expression of genes (Zaiss and 
Muruve, 2005). Similarly, LV constructs offer a safe clinical-grade alternative to deliver 
genes into non-dividing cells in neurodegenerative disorders (Lundberg et aI., 2008). 
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The gene coding for tyrosine hydroxylase is the first gene to be investigated in the quest 
for a gene therapy of PD, and has shown promising results in vitro and in vivo (Kang et 
aI., 2001). Further, levels of AADC, the enzyme that catalyzes the decarboxylation of 
levo-dopa and converts it to DA, are diminished in the brains of PD patients. Indeed, 
AADC gene therapy has been shown to improve motor functions in MPTP-Iesioned 
primates (Bankiewicz et aI., 2006). These results led to the initiation of phase I clinical 
trials. Ten PD patients were treated with bilateral intraputaminal injection of human 
AADC-carrying AA V vector and displayed approximately 30% improvement in the on-
medication (at day times of drug peak plasma concentration such as one hour after taking 
a drug dose) and off-medication (at day times of lowest drug plasma concentration such 
as early morning) states based on the UPDRS. However, headaches and increased risks 
of cerebral hemorrhage were reported as side effects (Christine et aI., 2009). Another 
phase I clinical study employing AA V -mediated intraputaminal delivery of AADC 
carried out in 6 PD patients were well tolerated and 46% improvement in functional 
performance in the off-medication state, based on the UPDRS scores was reported 
(Muramatsu et aI., 2010). 
A combinatorial approach involving infusion of the three main enzymes required in 
dopamine synthesis, viz. TH, guanosine triphosphate (GTP) cyclohydrolase 1, and 
AADC using a tricistronic LV vector resulted in significantly higher motor recovery in 
primate models of PD, compared to single gene delivery (Jarraya et aI., 2009; Muramatsu 
et aI., 2002). GTP cyclohydrolase 1 is an enzyme needed to convert GTP to 
tetrahydrobiopterin (BH4), a cofactor involved in the tyrosine hydroxylase-catalyzed 
production of levo-dopa from L-tyrosine (Levine et aI., 1981). Pre-published reports on a 
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currently ongomg phase IIII clinical trial, that implements a similar combinatorial 
strategy, revealed motor improvement in UPDRS scores in all cohorts at 6 months post 
therapy (Oxford BioMedica, 2011), highlighting the advantage of combinatorial 
approaches over single gene delivery. A schematic representation of the tricistronic 
approach is shown in figure 2. 
~-.---~ 
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Figure 2. A tnei~tronic appwaeh w .. ing the three gene!"> responsible for dopamine synthe~is. tyro~lIle 
hydrllxyla~c , aromatic amino acid decarboxylase and GTP cyclohydrolasc I , ha~ becn investigated in PO 
patients. (TH : tyrosillc hydroxylase. AAOC: aromatic amino aeid decarboxylasc, GCH I: GTP 
cyclohydrolase I. LV : lentivirus. Pfl)savin: the brand namc of the preparation) 
Since PD pathology is associated with overactivity of the subthalamic nucleus and the 
globus pallidus pars intern a (Hammond et aI., 2007), it was hypothesized that inhibiting 
the subthalamic nucleus through introduction of the GAD gene that converts glutamic 
acid into GABA, the major inhibitory transmitter in the eNS, will alleviate the symptoms 
of PD (figure 3). Indeed, functional improvements have been reported following AA V2-
mediated delivery of GAD gene in murine (Lee et aI., 2005) and primate (Emborg et aI., 
2007) models of PD, leading to the commencement of clinical trials . In a phase I trial of 
unilateral infusion of the GAD-viral vector into the subthalamic nucleus, no adverse 
effects were reported and significant motor improvements were observed up to 12 months 
post-treatment (Kaplitt et aI., 2007). In addition, a recent double-blinded clinical trial 
implementing the AA V2-mediated bilateral subthalamic nucleus delivery of GAD 
showed positive results with a 23.1 % mean improvement of UPDRS motor score in the 
20 
off-medication state, cQmpared to 12.7% in the control group at 6 months post-treatment 
(LeWitt et aI., 2011). These results are probably the most promising results observed in a 
controlled double-blinded trial in the search for an effective gene therapy for PD. 
However, the improvement shown in the GAD-delivery study seem to be approximately 
half of what was observed with surgical deep brain stimulation (Limousin et aI., 1998), 
raising skepticism about the future of gene-therapy approaches in PD. 
inhibition 
Figure 3. lnhibiting the subthalamic nucleus (STN) and/or the globu~ pallidu~ interna via deep brain 
stimulatioll or via delivery of glutamic acid decarboxylase encoding gene is useful to treat PD. 
Taken together, these studies indicate the potential for using gene therapy to treat PD in 
the future. However, improved long-term stable expression of target gene as well as 
confirmation of their safety are required for the success of effective and safe gene-
therapy approaches in the treatment of PD. 
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CHAPTER III 
CELL REPLACEMENT THERAPY FOR PD 
The failure of known pharmacological and surgical measures to halt and/or reverse the 
progressive loss of neurons and the associated pathophysiology in PD patients makes it 
imperative to search for novel therapeutic approaches. Cell replacement therapy appears 
to be promising in this regard as it offers a means to replace degenerative dopaminergic 
neurons, especially in the SNpc, where the initial neurodegeneration occurs in PD (Chiu 
and Hall, 2006). Double-blind placebo-controlled clinical trials that implemented the 
intracerebral implantation of human dopaminergic neurons-containing grafts in several 
PD patients (Freed et aI., 2001; Olanow et aI., 2003) provided proof-of-principle for the 
potentials of cell replacement therapy in PD, albeit with a few remaining challenges. 
I. Tissue grafts 
The earliest cell replacement therapy for PD employed autologous chromaffin cell-
containing adrenal medulla tissue and was reported as a success when grafted in 2 PD 
patients (Madrazo et aI., 1987). Subsequently, hundreds of patients were grafted based on 
the same approach. However, the grafts were found to be a failure due to the associated 
morbidity and the lack of significant behavioral recovery (Goetz et aI., 1991). 
The trend then shifted toward grafting fetal mesencephalic tissue collected from 8- to 9-
week-old fetuses (Lindvall et aI., 1990). The first clinical trials implementing fetal tissue 
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grafting was carried out more than twenty years ago and showed promising recovery in 
some patients (Lindvall et aI., 1990). Furthermore, fetal mesencephalic graft neurons 
survived in the host striatum for a long period of time and induced positive motor 
improvement (Hagell et aI., 1999; Hauser et aI., 1999). In fact, some patients improved 
satisfactorily for more than ten years after the transplantation (Mendez et aI., 2008). 
However, double-blind fetal midbrain grafting studies sponsored by the National Institute 
of Health (NIH) showed variable effects as well as induction of distressing side effects 
such as graft-induced dyskinesia. Indeed, graft-induced dyskinesia was reported in 56% 
of the treated subjects and some cases necessitated surgical intervention by deep brain 
stimulation (Freed et aI., 2001; Olanow et aI., 2003). Advanced PD patients with 
widespread neurodegeneration outside the nigrostriatal system and those with a history of 
levo-dopa-induced dyskinesia are more likely to experience graft-induced dyskinesia. 
Hence, it is imperative to apply strict inclusion criteria that avoid patients with high risk 
of developing graft-induced dyskinesia (Wakeman et aI., 2011). The cause of the 
dyskinesia is likely the "overload" due to excess dopamine secretion into the striatum 
and/or the unavoidable presence of serotonergic neurons within the fetal ventral 
mesencephalic grafts (Lane et aI., 2010). In fact, serotonergic neuron-rich grafts do not 
exert therapeutic effect and cause deterioration of levo-dopa-induced dyskinesia in a rat 
model of PD (Carlsson et aI., 2007). Moreover, a 2: 1 ratio of dopaminergic neurons to 
serotonergic neurons markedly reduced levo-dopa induced dyskinesia, indicating that the 
relative ratio of dopaminergic neurons to serotonergic neurons (not the absolute number 
of serotonergic neurons) is what drives dyskinesia (Carlsson et aI., 2009). Interestingly, 
systemic administration of buspirone, a serotonergic receptor 5-HTIA agonist that 
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dampen transmitter release from serotonergic neurons, markedly attenuated graft-induced 
dyskinesia (Politis et aI., 2010). Hence, it is recommended to exclude, as much as 
possible, serotonergic neurons from transplants. Moreover, standardization of the 
parameters for graft collection, preparation and storage IS needed to control the 
dopaminergic: serotonergic composition of grafted tissues. 
Importantly, detection of cellular PD-related pathological features in a few grafted cells 
in the brains of treated patients, ten years after transplantation (Kordower et aI., 2008; Li 
et aI., 2008), led to the conclusion that the surrounding brain microenvironment has a 
deleterious effect on the survival of grafted and endogenous dopaminergic neurons in PD 
patients. This report was contradicted by another study which did not detect any 
pathological features in the grafted neurons (Mendez et aI., 2008). Nevertheless, ethical 
concerns as well as issues associated with the availability of 8-9 week old fetal tissue 
made it impractical to continue investigating fetal midbrain-derived grafts in clinical 
therapy (Astradsson et aI., 2008; Deierborg et aI., 2008), raising the need for more 
practical sources for cell replacement therapy in PD. 
II. Stem cells (SCs) as a source of cell replacement therapy in the treatment of PD 
The ethical and practical impediments associated with fetal grafting in PD shifted the 
attention of the cell replacement therapy field to the use of SCs, widely viewed as a 
therapeutic strategy with immense potential in the treatment of neurodegenerative 
diseases. The general strategy is to harvest SCs and induce them to differentiate into 
dopaminergic neurons that could be transplanted in the brain to replace, protect or repair 
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endogenous dopaminergic neurons III the SNpc III order to halt and/or reverse the 
progressive nature of the disease. 
Over the past decade, several types of SCs have been investigated as potential candidates 
for cell replacement therapy in PD, including pluripotent embryonic SCs (ESCs), induced 
pluripotent SCs (iPSCs), and multipotent neural (N) and mesenchymal (M) SCs. 
Pluripotent SCs, such as ESCs, give rise to all cell types within the three germ layers, 
whereas multipotent tissue-specific SCs such as NSCs give rise to all cell types within 
their respective tissue. There is some evidence that multipotent SCs possess the ability to 
trans differentiate when given the right conditions, albeit with little efficiency (Cogle et 
aI., 2004; Priller et aI., 2001), indicating the possibility of using non-neural multipotent 
SCs, such as MSCs, to induce dopaminergic neuronal differentiation in the treatment of 
PD. A summary of the different types of stem cells investigated in the treatment of PD 
and their advantages and disadvantages are presented in table 1. 
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fahle 1. Summar:v of tl1(' a(hantag('s and disadvantage of stern n-II" im esl.igated in the treatment of 
PD. 
Type potency Main source Advantages Disadvantages 
embryonic pluripotent embryonic blastocyst - high dopaminergic - tumorigenic 
stem cells yield 
- ethical issues 
- effective in animal 
models - poor survival in vivo 
induced pluripotent reprogrammed - autologous - low dopaminergic 
pluripotent somatic cells transplantation yield 
stem cells 
- no ethical issues - time consuming 
- effective in animal - labor intensive 
models 
- costly 
- tumorigenic 
- poor survival in vivo 
mesenchymal multi potent bone marrow and - autologous - low dopaminergic 
stem cells umbilical cord transplantation yield 
- possess anti- - poor survival in vivo 
inflammatory properties 
- not tumorigenic 
- safe 
- effective in animal 
neural stem multipotent adult brain - autologous - low dopaminergic 
cells transplantation yield 
- differentiate into the - poor survival in vivo 
three lineages of the 
nervous system - hard to identify and 
isolate 
- effective in animal 
models - tumorigenic 
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IIa. Embryonic Stem Cells 
ESCs are derived from the inner cell mass of the blastocyst (figure 4) and are 
characterized by self-renewal (indefinite proliferation while maintaining their identity), 
and pluripotency (ability to differentiate into all cells of the three germ layers). The main 
advantages of ESCs as a source for cell replacement therapy in PD are their pluripotency 
and high rate of proliferation (Newman and Bakay, 2008). So far, among all types of 
SCs, ESCs have yielded the most promising results in terms of their efficiency to 
differentiate into dopaminergic neurons . In fact, protocols for inducing dopaminergic 
neuronal differentiation of SCs have mostly been developed using ESCs (Perrier et aI., 
2004; Schulz et aI., 2004; Yan et aI., 2005). 
Zygote Blastocyst 
Figure .... When the Iygnle i~ formed during conception, il ~Iarl~ In diVIde rapidly and form~ lhe hlastoc)sl. 
Emhryonie stem cells are derived from lhe inner cell mass of the hlastocyst. 
To achieve best results, ESCs must gIve n se to A9-subtype midbrain dopaminergic 
neurons that could replace or prevent the progressive loss of dopaminergic neurons in the 
SNpc region of PD patients (Mendez et aI., 2005). Hence a major focus has been placed 
on inducing ESCs to differentiate into dopaminergic neurons before injecting them into 
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the patient midbrain. The differentiation of SCs into dopaminergic neurons is promoted 
by culturing them on stromal feeder layers (Kawasaki et aI., 2000), in the presence of 
specific dopaminergic neuronal fate-driving growth factors such as sonic hedgehog 
(SHH) (a regulator of cell division and organogenesis) and FGFS (Lee et aI., 2000), 
and/or through the expression of transcription factors such as Lmxla and Nurrl 
(transcription factors that play an active role in the differentiation of midbrain precursors 
into dopaminergic neurons) (Andersson et aI., 2006; Kim et aI., 2002). Not only do 
growth factors promote neuronal differentiation but they also potentiate the survival rate 
of grafted cells, thus inducing better functional recovery in animal models of PD. For 
instance, adding FGF2, FGF20 and Wnt5a to parthenogenetic primate SCs at their final 
stages of differentiation enhance survival of the grafted cells and consequently, improve 
motor function in 6-0HDA-Iesioned rats (Sanchez-Pernaute et aI., 200S). The highest 
differentiation efficiency has been achieved using genetically-modified Nurr 1-
overexpressing mouse ESCs, co-cultured with P A6 stromal cells in a medium enriched 
with shh, fgfS and ascorbic acid (Kim et aI., 2006). The study resulted in -90% 
dopamine-secreting neurons that integrated successfully upon transplantation in the brain 
of a rat model of PD. 
In vivo studies have revealed the ability of ESCs to differentiate efficiently into 
dopaminergic neurons which in turn could be used to treat parkinsonian symptoms in 
animal models. For instance, upon transplantation of ESC-derived dopaminergic neurons 
in the striatum of unilaterally 6-0HDA-Iesioned rats, Rodriguez-Gomez et aI. confirmed 
appropriate dopamine release and reuptake by the transplanted cells as well as their 
ability to stimulate postsynaptic dopaminergic D2 receptors (Rodriguez-Gomez et aI., 
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2007). Importantly, the study showed that the implanted dopaminergic neurons survived 
for 32 weeks after transplantation and induced marked behavioral recovery. Similarly, 
over 70% reductions in chemical-induced rotational behavior and improved motor 
function were observed when ESC-derived dopaminergic neurons were implanted 
intrastriatally in a rat model of PD (Barberi et aI., 2003). In primates, ESCs co-cultured 
with PA6 cells in the presence of FGF2 and FGF20 differentiated successfully into 
dopaminergic neurons, that survived in the brain and improved neurological deficits upon 
transplantation in the striatum of MPTP-Iesioned monkeys (Takagi et aI., 2005). 
Whereas the aforementioned studies show marked behavioral recovery in animal models 
of PD when transplanted with non-human neurons, use of human (h) ESC-derived 
dopaminergic neurons have yielded less encouraging results, probably due to 
histocompatibility issues. Groups who transplanted dopaminergic neurons derived from 
hESCs into the brains of hemiparkinsonian rats have reported either no therapeutic effect 
(Brederlau et aI., 2006; Park et aI., 2005) or modest functional improvement (Ben-Hur et 
aI., 2004). Although Roy et aI. reported long-term survival of many brain-grafted hESC-
derived cells in addition to a significant functional recovery in a rat model of PD (Roy et 
aI., 2006), subsequent studies questioned the results and conclusions drawn from the 
study and have suggested that the behavioral improvement observed was not dopamine-
dependent but probably due to graft-induced striatal damage (Morizane et aI., 2008). 
More recently however, Kriks et aI. were able to extend the in vivo survival of midbrain 
dopaminergic neurons derived from hESCs up to 5 months and these neurons were able 
to induce significant motor improvement in parkinsonian mice, rats and monkeys (Kriks 
et aI., 2011). This group proposed a novel protocol for deriving human dopaminergic 
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neurons from ESCs that recapitulated physiological conditions of dopaminergic neuronal 
development, thereby enhancing their long-term survivability both in vitro and in vivo. 
Several challenges are still facing the clinical application of ESC-based therapy in PD 
patients. To our knowledge, almost all previous investigations have reported poor 
survival of hESC-derived neurons following transplantation (Brederlau et aI., 2006; Park 
et aI., 2005), probably due to immunological rejection by the host tissues (Toriumi et aI., 
2009). To circumvent this issue, some studies emphasize the importance of identifying 
the optimal developmental stage of ESC-derived cells before transplantation. In this 
regard, dopaminergic neuronal precursors are thought to be more capable of avoiding the 
premature death of cells after transplantation as compared to the mature dopaminergic 
neurons (Jonsson et aI., 2009). Moreover, ethical concerns associated with the use of cells 
obtained from human embryos for cell replacement therapy have made clinical 
application of ESCs difficult (Fukuda and Takahashi, 2005). 
In addition to the aforementioned impediments, the risk of teratoma (potentially fatal 
benign tumors containing a mixture of tissue types, formed after injection of SCs in 
animal models) formation after transplanting ESC-derived transplants poses the greatest 
challenge to clinical cell replacement therapy for PD patients. In fact, human ESCs share 
many cellular and molecular similarities with cancer cells such as high proliferative 
potential (Amit et aI., 2000), genomic instability (Harrison et aI., 2007), epigenetic status 
(Calvanese et aI., 2008), and high telomerase activity (Hiyama and Hiyama, 2007). 
Therefore, it is generally accepted that in vitro differentiation of ESCs into more mature 
dopaminergic precursors or neurons must be carried out before grafting. Furthermore, 
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excluding all undifferentiated ESCs before transplantation is essential to avoid the 
formation of teratomas. 
A number of approaches have been proposed to eliminate undifferentiated ESCs. For 
instance, fluorescence-activated cell sorting (FACS) techniques have been implemented 
to exclude undifferentiated SCs and neural precursors based on cell surface markers 
(Fukuda et aI., 2006). A second approach to eliminate pluripotent cells involves killing 
them through the use of cytotoxic antibodies (Tan et aI., 2009) or induction of selective 
apoptosis of undifferentiated cells through the use of the cerami de analogue, N -oleoyl 
serinol (S 18) (Bieberich et aI., 2004). A third approach involves Cripto, a protein known 
to inhibit ESCs differentiation and enhances tumorigenicity after transplantation. Indeed, 
Cripto knockout ESCs have been shown to differentiate successfully into dopaminergic 
neurons without inducing tumorigenesis when implanted into 6-0HDA-Iesioned rats 
(Parish et aI., 2005). Novel approaches based on studies addressing the molecular basis of 
tumorigenesis will enable suppression of tumorigenic genes in ESC-derived neurons in 
transplantation therapy. 
lIb. Induced Pluripotent Stem Cells 
The discovery of iPSCs has presented an invaluable source for cell replacement therapy 
that avoids the ethical issues associated with the use of ESCs. The general concept of 
using iPSCs in the treatment of PD is to reprogram the patient's own adult somatic cells 
into a pluripotent state and then induce them to differentiate into dopaminergic neurons 
that could be transplanted into the patient's brain (figure 5). Mouse somatic fibroblasts 
were the first to be reprogrammed into iPSCs through retroviral transduction of four 
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transcription factors, namely octamer-binding transcription factor 4 (Oct4), SRY box-
containing gene 2 (Sox2), Kruppel-like factor 4 (Klf4), and c-Myc (Takahashi and 
Yamanaka, 2006; Wernig et aI., 2007). In addition to fibroblasts, several other cell 
lineages have subsequently been reprogrammed into a pluripotent state by overexpressing 
some or all of the aforementioned four transcription factors (Golestaneh et aI., 2009; 
Kunisato et aI., 2010; Yamanaka et aI., 2008). Newer reprogramming protocols such as 
methods requiring no viral integration as well as strategies using small molecules to 
promote reprogramming efficiency are being developed to enhance the clinical potential 
of iPSCs, raising the possibility that they may replace ESCs in cell replacement therapy 
in the near future (Nishikawa et aI., 2008; Wernig et aI., 2008; Yamanaka, 2008). 
The iPSCs are similar but not identical to ESCs in morphology, proliferative potential, 
telomerase activity, cell surface markers, gene expression, and epigenetic status (Kim et 
aI., 2010; Takahashi et aI., 2007). Although micro array studies have shown that iPSCs 
exhibit a gene-expression profile that is similar to ESCs (Hochedlinger and Plath, 2009), 
they are less robust than ESCs in terms of differentiation potential and effectiveness in 
cell replacement therapy. In fact, an increased body of literature shows that iPSCs exhibit 
their own unique gene expression and DNA methylation pattern that are different from 
ESCs (Chin et aI., 2009; Doi et aI., 2009). These small differences might be attributed to 
the genomic integration of reprogramming transcription factor genes or to the unique 
genetic makeup of the cells prior to reprogramming. 
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fibroblasts ) iPSCs ) DAneurons 
Figure 5. Transduction of four transcnplillfl factors into fibroblasts result~ in the forillation of induced 
pluripotent stem cells which can subsequently be inLluced to differentiatc into dopaminergic neurons to 
replace L1egeneratcLi neuron~ ill Parkinson's disease. 
The iPSC technology offers a number of advantages for cell replacement therapy in PD. 
First, it avoids the ethical controversies associated with the use of ESCs in cell 
replacement therapy for PD. Furthermore, the use of iPSCs makes it feasible to carry out 
autologous transplantation, thereby eliminating the risk of graft rejection by the recipient 
immune system (Dimos et aI., 2008; Park et aI., 2008b). In fact, iPSCs obtained from PD 
patients have been shown to differentiate as efficiently as healthy individual-derived 
iPSCs and displayed no PD-related pathological features in vitro (Soldner et aI., 2009). 
When PD patient' s iPSC-derived cells were intrastriatally transplanted in a murine model 
of PD, substantial attenuation of motor deficits were observed up to 16 weeks after 
transplantation (Hargus et aI., 2010). Although further studies are needed to establish 
their long-term functionality, these exciting observations highlight the curative potential 
of iPSCs and justify their use as a viable cell replacement strategy in the treatment of PD. 
Several in vivo studies have shown promising results with the use of iPSCs in the 
treatment of PD. For instance, Wernig et aI. managed to promote the differentiation of 
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iPSCs into neuronal precursors and dopaminergic neurons in vitro. Following subsequent 
in vivo implantation, iPSC-derived cells migrated into several brain tissues, integrated 
properly, and improved behavioral recovery in 6-0HDA-lesioned rats. Although initial 
observations showed the occurrence of teratomas in the grafted areas, depletion of all 
undifferentiated cells using FACS resulted in functional improvement without tumor 
formation up to 8 weeks after transplantation (Wernig et aI., 2008). More recently, 
Swistowski et al. were successful in generating dopaminergic neurons from human 
(h)iPSCs, and the intracerebrally transplanted neurons survived and improved 
parkinsonian symptoms in a rat model of PD (Swistowski et aI., 2010). Similar results 
were obtained by Cai et al. by transplantation of commercially available hiPSCs line-
derived dopaminergic progenitor cells into the brains of 6-0HDA-lesioned rats (Cai et 
al.,201O). 
As with any new emergent technology, the iPSC technology also suffers from several 
technical and safety limitations that hinder its clinical use in patients with PD. For 
example, progenitors derived from hiPSCs are prone to earlier senescence than those 
from hESCs (Feng et aI., 2010). Furthermore, compared to hESCs, hiPSCs differentiate 
into midbrain dopaminergic neurons with very low efficiency, rendering the clinical 
application of iPSCs costly and impractical. The low dopaminergic yield obtained from 
iPSCs may be attributed to the activation of anti-reprogramming or tumor-suppressive 
cellular mechanisms (Chen et aI., 2011). In addition, integration of viral genomic material 
in the iPSCs may also playa role in altering their differentiation potential. 
Due to their pluripotent potential, engrafted iPSCs also exhibit a tendency to generate 
teratomas comprised of the three fetal germ layers (Takahashi et aI., 2007; Takahashi and 
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Yamanaka, 2006). In fact, several recent reports indicate a higher tumorigenicity risk 
associated with iPSCs than with ESCs (Gutierrez-Aranda et aI., 2010; Ohm et aI., 2010). 
In addition to pluripotency-related tumorigenesis, tumor formation may also occur as a 
result of genomic integration of the viral vector DNA into the iPSCs and/or due to the 
mitogenic properties of the transcription factors used in reprogramming (Gottweis and 
Minger, 2008). In fact, two of the four reprogramming transcription factors, namely c-
Myc and Klf4, are oncogenic and several protocols have been proposed to minimize or 
avoid their use in reprogramming. Fortunately, c-Myc-free reprogramming protocols 
have been tested and proven successful in generating iPSCs, albeit slower and less 
efficient (Nakagawa et aI., 2008). Furthermore, Oct4 and Sox2 are sufficient for 
reprogramming human fibroblasts without the need for c-Myc or Klf4, when valproic 
acid, a histone deacetylase inhibitor, was present (Huangfu et aI., 2008). These 
observations, together with the potential use of small molecules in generating iPSCs, 
raise the possibility of minimizing or eliminating the need for oncogenic factors in cell 
reprogrammmg. 
Since the use of integrating retroviruses m reprogrammmg IS also associated with 
tumorigenicity (Yu et aI., 2007), attempts have been made to generate iPSCs through the 
use of nonviral or nonintegrating viral vectors, albeit with lower efficiency. Jia et aI. used 
DNA minicircle vectors, supercoiled molecules primarily composed of eukaryotic 
expression cassette, to generate trans gene-free iPSCs from human adipose SCs (Jia et aI., 
2010). The resulting minicircle iPSCs subclones showed a high degree of similarity to 
hESCs in global gene expression with no genomic integration of the transgenes. 
However, the reprogramming efficiency achieved (-0.005%) was lower than that of viral-
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based reprogramrrung (-0.01 %). In addition, removmg reprogramrrung transcription 
factors after reprogramrrung using Cre-recombinase excisable viruses has been 
accomplished (Soldner et aI. , 2009). The resultant factor-free hiPSCs maintained a 
pluripotent state and showed an overall transcription profile closely related to hESCs 
rather than that of transgenic hiPSCs. More recently, induction of iPSCs was achieved 
through the use of protein-based programming without the need for gene-manipulation 
(Cho et aI. , 2010). The study proposed that transfer of ESC-derived proteins into mouse 
fibroblasts could result in reprogramming to a pluripotent state without the risk of 
tumorigenicity associated with the use of exogenous transcription factors. Other non viral 
or nonintegrating viral vectors recently used to generate iPSCs include non-integrating 
adenoviruses (Stadtfeld et aI. , 2008), plasmids (Okita et al. , 2008), episomal vectors (Yu 
et aI. , 2009) , synthetic modified rnRNA (Warren et aI. , 2010), piggyBac transposition 
(Woltjen et aI. , 2009) , and miRNA (Anokye-Danso et al. , 2011 ). Selected methods for 
reprogramming cells into iPSCs are presented in table 2. 
Table 2. Some methods for reprogramming human and murine somatic cells into iPSCs and their 
efficiencies. if available. 
Reprogramming 
Source of iPSCs Reprogramming method efficiency Refs. 
human and embryonic 
miRNA-mediated 
Anokye-Danso et aI. , 
somatic cell s 
reprogramming 2: 0.1% 
2011 
nonviral DNA minicircle 
human adipose stem vectors carrying OCT4, SOX2, 
0.005 % Jia et aI. , 2010 
cells NANOG, and L1N28 
multiple human cell 
types synthetic modified mRNA 1.4% Warren et aI. , 2010 
mouse cardi ac 
fibroblasts 
protein-based reprogramming Cho et aI. , 2010 
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mouse adult bone retroviral transduction of oct4, 0.067% Kunistao et aI., 2010 
marrow mononuclear sox2, klf4, and c-myc 
cells 
human adult testes embryonic stem cell medium 0.5-1 % Golestaneh et aI., 2009 
enriched with appropriate 
growth factors (basic FGF) 
human PD patients cre-recombinase excisable 0.01% Soldner et aI., 2009 
fibroblasts lentiviral viruses transducing 
OCT4, SOX2, KLF4, and C-
MYC 
human PD patients cre-recombinase excisable 0.005% Soldner et aI., 2009 
fibroblasts lentiviral viruses transducing 
OCT4, SOX2, and KLF4 
human and murine doxycycline-inducible WoItjen et aI., 2009 
embryonic fibroblasts transcription factors delivered 
by PiggyBac transposition 
mouse embryonic plasmids containing the < 0.000029% Okita et aI., 2008 
fibroblasts complementary DNA for oct4, 
sox2, klf4, and c-myc 
mouse fetal liver cells nonintegrating adenoviruses 0.0001-0.001 % Stadtfeld et aI., 2008 
expressing oct4, sox2, klf4, and 
c-myc 
human fibroblats retroviral transduction of OCT4, 1% Huangfu et aI., 2008 
SOX2, and KLF4, in the 
presence of valproic acid 
human fibroblasts retroviral transduction of OCT4, < 0.001% Nakagawa et aI., 2008 
SOX2, and KLF4 
human PD patients retroviral transduction of OCT4, Park et aI., 2008b 
fibroblasts SOX2, KLF4, and C-MYC 
mouse somatic retroviral transduction of oct4, 0.05-0.1% Wernig et aI., 2007 
fibroblasts sox2, klf4, and c-myc 
Another interesting approach to eliminate tumorigenicity of iPSCs is the direct 
reprogramming of somatic fibroblasts into dopaminergic neurons, thereby avoiding the 
formation of potentially tumorigenic pluripotent SCs (figure 6). To that end, mouse 
fibroblasts were directly reprogrammed in vitro to become neurons, without passing 
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through a potentially tumorigenic pluripotent state, by employing the transduction of 
three neural-lineage-specific transcription factors Ascll, Mytll and Bm2 (Vierbuchen et 
aI., 2010). The resultant neurons exhibited excitatory phenotype with cortical identity and 
formed functional synapses. Although the efficiency of reprogramming reached 19.5%, 
tyrosine hydroxylase-expression was not detected, indicating that dopaminergic neurons 
were not induced. Nonetheless , the study paves the road for more investigations to use 
neural cell-fate determining proteins to directly reprogram somatic cells into 
dopaminergic neurons. 
direct 
reprogran:nning 
Figure 6. Direct reprogramming of lihrohlasls into ncuron~ has the advantage of avoiding the formation of 
tumorigenic induced pluripotent stem cell),. 
The iPSC technology is labor-intensive, time-consuming and costly. Increasing the 
efficiency of reprogramming could help reduce the cost of generating iPSCs. To that end, 
more efficient protocols must be developed in the near future to advance the role of 
iPSC-based therapy in degenerative disorders. Interestingly, a recent report has indicated 
that miRNA could influence cellular reprogramming and generation of iPSCs. 
Consequently, small molecules promoting or inhibiting specific miRNAs may prove 
valuable in enhancing the efficiency of cellular programming (Mallanna and Rizzino, 
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2010). In addition to reducing the cost of iPSC technology, it is also imperative to 
understand and to circumvent the early senescence and tumorigenicity associated with 
iPSC-derived cells. 
lIe. Mesenchymal Stem Cells 
The use of MSCs in the quest for a cell replacement therapy -based treatment for PD is 
relatively new and less well-characterized. MSCs are responsible for generating tissues of 
the mesoderm and reside in adult (e.g. bone marrow, adipose tissue, peripheral blood, and 
liver), fetal (e.g. bone marrow, lung, spleen, liver, brain, and peripheral blood), and extra-
embryonic tissues (e.g. umbilical cord blood, amniotic fluid, and placenta). However, the 
main sources for cell replacement therapy are the umbilical cord and the adult bone 
marrow (Zhao and Xu, 2011). The multipotent MSCs normally differentiate into 
mesodermal osteocytes, adipocytes, chondrocytes, and myocytes and can also give rise to 
neuroectodermal neurons under the right conditions in vitro (Pittenger et aI., 1999; 
Sanchez-Ramos et aI., 2000; Woodbury et aI., 2000). MSCs have been shown to have 
inherent ability to repair neuronal damage (Phinney and Isakova, 2005), paving the road 
for their potential use in the treatment of PD. The use of MSCs offers multiple 
advantages over using other types of SCs in the treatment of PD. For instance, MSCs can 
be readily harvested and cultured in vitro (Bianco et aI., 2001). Moreover, no ethical 
limitations are associated with the use of autologous MSCs as opposed to hESCs or 
allogeneic NSCs. MSCs are poorly immunogenic due to the lack of major 
histocompatibility complex (MHC)-II expressIOn, reducing the need for 
immunosuppressive therapy (Morandi et aI., 2008). In fact, MSCs may possess inherent 
immunosuppressive activity, as shown by Zhang et ai. that MSCs inhibit mitogen 
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stimulated T lymphocyte proliferation (Zhang et aI., 2008). Importantly, no tumor 
formation or significant adverse side effects have been reported following the 
implantation of MSCs into the brains of PD animal models (Trzaska and Rameshwar, 
2007). 
A number of in V1VO studies have shown the ability of MSCs to induce therapeutic 
behavioral improvement in murine animal models of PD (Bouchez et aI., 2008; Li et aI., 
2001). Interestingly, human umbilical cord matrix-derived MSCs, transplanted into the 
brains of non-immunosuppressed murine models of PD, showed significant functional 
improvement with no tumor formation, confirming their immunomodulatory properties 
and potential for use in non-autologous transplantation (Weiss et aI., 2006). Noteworthy, 
reports have also indicated that grafted MSCs could migrate to the site of injury and 
enhance the number of tyrosine hydroxylase--positive neurons in the brain (Jin et aI., 
2008; Sadan et aI., 2009). Interestingly, even systemically-administered MSCs have been 
shown to promote behavioral recovery in a rat model of PD (Park et aI., 2008a). This 
observation led to the conclusion that certain chemokines secreted from the damaged 
brain tissues attract MSCs to the site of brain damage. 
More recently, genetically-modified MSCs have been investigated as a more robust 
therapeutic approach in the treatment of PD. For instance, intrastriatally transplanted 
vascular endothelium growth factor-expressing human umbilical cord-derived MSCs 
differentiated into dopaminergic neurons and ameliorated motor abnormalities in a rat 
model of PD (Xiong et aI., 2011). Similarly, intrastriatal implantation of GDNF-
expressing human bone marrow-derived MSCs in a rat model of PD resulted in the 
sprouting of rejuvenated tyrosine hydroxylase--positive neurons around the graft and 
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significant functional improvement in parkinsonian symptoms (Glavaski-loksimovic et 
aI., 2010). In addition, another group reported that transplantation of brain-derived 
neurotrophic factor-secreting MSCs into the SNpc of a murine model of PD resulted in 
enhanced grafting and neuroprotection (Somoza et aI., 2010). 
In addition to neurotrophic factors, the dopamine synthesizing enzyme, tyrosine 
hydroxylase, has also been overexpressed in MSCs. When tyrosine hydoxulase-
expressing bone marrow-derived MSCs were induced to differentiate into NSCs and 
injected into the brain lateral ventricle of parkinsonian rats, considerable behavioral 
recovery was observed, indicating the ability of injected modified NSCs to migrate 
through the cerebrospinal fluid brain barrier into the damaged SNpc (Zou et aI., 2010). 
Consequently, the study also highlights the possibility of less invasive approaches such as 
ventricular or even subarachnoid transplantation of SCs. Recently, a combination of 
tyrosine hydroxylase-- and GDNF-expressing MSC preparations were shown to have 
superior therapeutic effect than either alone when implanted into the striatum of a rat 
model of PD (Shi et aI., 2011). This study suggests synergism between tyrosine 
hydroxylase and GDNF in the treatment of PD. Similar synergy has been reported when 
using both tyrosine hydroxylase-- and brain-derived neurotrophic factor-expressing 
astrocytes in animal models of PD (Wang et aI., 2002). However, more conclusive 
studies comparing the effectiveness of normal versus genetically-modified SCs are 
needed. 
The exact mechanism of the therapeutic effects of MSCs in neurodegenerative disorders 
such as PD is still controversial. Some studies indicate that MSCs exert their beneficial 
effect by expressing neurotrophic factors that exert neuroprotective effects on 
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dopaminergic neurons (Pereira et aI., 2011). Consistent with that, MSCs exhibit a unique 
genetic expression profile enriched in angiogenic and neurogenic genes (Secco et aI., 
2009). A number of reports have proposed that MSCs act by enhancing axonal growth of 
the dopaminergic neurons (Sasaki et aI., 2009; Shen et aI., 2006). In addition, the anti-
inflammatory effect of MSCs by reducing microglial activation has been proposed as a 
means for their immunomodulatory activity and thus, therapeutic effects in PD (Park et 
aI., 2008a). Interestingly, when transplanted into the striatum of a rat animal model, 
MSCs showed no differentiation into dopaminergic neurons (Blandini et aI., 2010). This 
study also showed that whereas some of the grafted MSCs differentiated into glial-like 
cells, the grafted cells still exerted anti-parkinsonian effect. Taken together, these results 
indicate that MSCs do not necessarily act by replacing dopaminergic neurons but rather 
by protecting the remaining dopaminergic neurons or by reversing degeneration. 
Although, in vitro and in vivo animal studies have reported promising results with the use 
of MSCs in the treatment of PD, preliminary human clinical trials have yielded 
controversial results. A recent study evaluated the use of autologous bone marrow MSC 
transplantation in the striatum of 7 patients (Venkataramana et aI., 2010). After an open-
label 12- to 36-month period of observation, only modest behavioral improvement was 
observed. This might have originated from a placebo effect because the magnetic 
resonance imaging scan did not show any differences in the brain pre- and post-
operatively, indicating that the grafts may not have survived in the brain after the surgical 
procedure. Fortunately, no adverse effects or tumor-like formations were detected during 
the course of the study. This study indicates that more investigations are still needed 
before MSCs could be clinically employed to treat patients with PD. 
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lId. Neural stem cells 
NSCs are multi potent SCs present in specific areas of the brain, including the 
subventricular zone and the subgranular zone of the hippocampal dentate gyrus (Eriksson 
et aI., 1998; Roy et aI., 2000). However, NSCs obtained from the ventral mesencephalon 
are thought to differentiate more efficiently into dopaminergic neurons as compared to 
those harvested from other parts of the brain (Jonsson et aI., 2009). Utilizing fetal or adult 
NSCs is thought to be a promising approach in the treatment of neurodegenerative 
disorders due to their potential for self-renewal and differentiation into the three cell 
lineages of the nervous system, viz., neurons, astrocytes, and oligodendrocytes (Gu et aI., 
2009; Lie et aI., 2002). More importantly, NSCs are associated with lower tumor-
formation risks after transplantation as compared to ESCs (Morizane et aI., 2008). In 
addition, the use of PD patient-derived NSCs paves the way for autologous 
transplantation and minimizes the need for immunosuppressive therapy (Arias-Carrion 
and Yuan, 2009). Of note, since embryonic NSCs are associated with serious ethical 
concerns, efforts have focused on developing methods to promote differentiation of adult 
NSCs into dopaminergic neurons that could be used in the treatment of PD (Trzaska and 
Rameshwar, 2007). 
In 1998, Studer et aI. first reported the generation of tyrosine hydroxylase--positive cells 
from embryonic rat mesencephalic precursors that exerted functional motor improvement 
when transplanted in a rat model of PD (Studer et aI., 1998). Several subsequent studies 
have confirmed the potential therapeutic effects of NSCs in PD. The intrastriatally 
transplanted neuroepithelial SCs derived from mouse embryonic neural tube has been 
shown to differentiate into dopaminergic neurons and to promote functional recovery in 
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6-0HDA-lesioned rats (Sun et aI., 2007). In addition to their ability to differentiate into 
dopaminergic neurons, NSCs have been suggested to exhibit neuroprotective effects in 
vivo (Yasuhara et aI., 2006). The study showed that supernatants from human NSC 
cultures exhibited neuroprotective effects on embryonic rat ventral mesencephalon 
dopaminergic neurons when exposed to 6-0HDA toxicity in vitro. Following 
transplantation into the brains of animal models of PD, most implanted human NSCs 
either remain undifferentiated as neural progenitors or differentiate into non-neuronal 
glial cells (Bjugstad et aI., 2008). To overcome low dopaminergic yield of differentiating 
NSCs, O'Keeffe et aI. overexpressed the transcription factor Pitx3 in rat embryonic NSCs 
derived from the ventral mesencephalon and co-cultured them with developing rat ventral 
mesencephalon tissue (O'Keeffe et aI., 2008). The experiment showed an enhancement in 
the yield of A9 dopaminergic neurons in vitro and a marked functional recovery 
following transplantation in 6-0HDA-lesioned rats, probably due to secretion of 
neurotrophic factors by the developing ventral mesencephalon. 
Recently, genetically-engineered rat NSCs that overexpress neurotrophin-3 were shown 
to be superior to non-modified NSCs in terms of regenerating dopaminergic neurons and 
inducing functional recovery when transplanted in a rat model of PD (Gu et aI., 2009). 
The study also demonstrated that neurotrophin-3-expressing NSCs were able to migrate 
towards the damaged areas of the brain. Similarly, GDNF-expressing NSCs were shown 
to enhance the survival of grafted dopaminergic neurons in vivo (Ostenfeld et aI., 2002), 
and neurturin-expressing NSCs to improve functional recovery in parkinsonian rats (Liu 
et aI., 2007). 
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However, the use of NSCs in cell replacement therapy of PD faces several practical and 
technical impediments. For instance, NSCs tend to lose their potential to give rise to 
dopaminergic phenotype following in vitro expansion and tend to differentiate primarily 
into glial cells in vivo (Bjugstad et aI., 2008; Chung et aI., 2006). Although it is generally 
accepted that the more differentiated SCs would exert better therapeutic effects as 
compared to undifferentiated SCs when transplanted in the brains of PD animal models, 
early senescence of mature dopaminergic neurons is still a significant issue that has to be 
resolved (Wang et aI., 2008). In fact, when compared to murine NSCs, human NSCs have 
shorter telomeres indicating earlier senescence liability (Ostenfeld et aI., 2000). 
Moreover, the effectiveness of NSCs transplantation is controversial since they already 
exist in the brains of PD patients. However, one could argue that they are not produced in 
sufficient quantities in the affected areas to halt the progressive degeneration of neurons 
in PD patients. Another argument is the inability of endogenous NSCs to migrate long 
distances to reach the damaged brain areas. Future studies should propose strategies to 
enhance the viability and efficiency of differentiation of NSCs into dopaminergic neurons 
to make their use more practical in the treatment of PD. 
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CHAPTER IV 
DISCUSSION 
The advent of iPSC technology, together with the improved purification and 
differentiation procedures, have made the potential for the therapeutic use of SCs in the 
treatment of neurodegenerative disorders such as PD more imminent than ever. 
However, several issues need to be addressed before SC-based cell replacement therapy 
can be a clinically feasible reality in the treatment of PD. 
One major obstacle facing SC-based therapy is the senescence and/or loss of cell viability 
of transplanted cells within few weeks following transplantation. This may be attributed 
to several factors including hypoxia, apoptosis, immune rejection, deficiency of trophic 
factors, or oxidative stress (Sonntag et aI., 2005). Although the exact cause of early loss 
of cell viability among transplanted neurons is not well understood, a few reports have 
suggested the addition of exogenous factors to promote the survival of dopaminergic 
neurons. For instance, Sanchez-Pernaute et aI. reported that exposure of primate SCs to 
FGF2, FGF20 and Wnt5a (a signaling protein that regulates cell fate and patterning) at 
the final stages of in vitro differentiation process enhanced their survival and thus 
resulted in improved functional recovery in a rat model of PD (Sanchez-Pernaute et aI., 
2008). To overcome low survival of transplanted cell, further investigations are needed to 
determine the proper developmental stage of SC differentiation for transplantation, 
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identify the exact mechanism of early graft cell death, and propose methods to improve 
their survival in host tissues. 
The induction of an immunological reaction against the graft could be one reason for the 
failure of SC therapy (Bradley et aI., 2002; Drukker et aI., 2002). It is therefore, useful to 
reduce immunological responses exerted by host tissues towards grafts by using 
autologous transplantation. Immune rejection may also arise from the presence of animal 
products during the manipulation of SCs or from allogeneic transplantation (Preynat-
Seauve et aI., 2009), indicating the necessity for animal product-free transplants. In order 
to reduce allogeneic transplantation-induced rejection in clinical therapy, blood group 
compatible transplants should be used. Any induced trauma during the surgical 
implantation of SCs could also trigger an inflammatory response that may amplify MHC 
expression of both transplanted and recipient tissue cells (McLaren et aI., 2001). When 
needed, the use of immunosuppressive therapy during and after surgery must be applied 
to reduce immune rejection and the patients must be closely monitored for compromised 
immunity-triggered complications. 
Protocols and instruments used for the preparation of SC implants should be improved in 
order to guarantee purity (dopaminergic neurons and/or precursors) and safety of the SC 
preparations to avoid potential undesirable adverse effects. Traditionally, mouse 
embryonic fibroblasts have been used as a supportive feeder layer for human pluripotent 
SCs as they offer a cellular substrate for SC adhesion, mimicking physiological milieu, 
and release suitable nutrients into the medium to support self-renewal and survival of SCs 
(Abraham et aI., 2010). Animal-derived contamination of grafted cells may lead to the 
transmission of animal retroviruses and other pathogens to patients. Therefore, several 
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studies have proposed several protocols to avoid the use of animal products during the 
culture and differentiation of SCs (Abraham et aI., 2010; Lei et aI., 2007; Mallon et aI., 
2006; Unger et aI., 2008). Furthermore, SC-derived implants, considered as a therapeutic 
product, must be prepared aseptically during manipulation and transplantation, to 
eliminate the risk of infection. Even the presence of fibroblasts in a human umbilical 
cord-derived MSC graft yielded undesirable results in animal models of PD (Pereira et 
aI., 2011). This study showed that the presence of fibroblasts reversed the therapeutic 
effects of MSCs and promoted neuronal degeneration of the basal ganglia. These authors 
proposed that the presence or absence of fibroblasts in implants could be the reason for 
contradictory results achieved by different groups assessing the efficiency of MSCs in the 
treatment of PD. 
Transplantation of pluripotent SCs and dopaminergic progenitors is accompanied by the 
risk of tumorigenicity. Hence, depleting residual undifferentiated pluripotent and/or 
progenitor populations (figure 7) is crucial to prevent the potential for tumor formation 
(Allan et aI., 2010). However, it has been shown that using FACS to enrich mouse 
dopaminergic neurons could result in diminished neuronal survival profile (Hedlund et 
aI., 2008). Although it is generally accepted that the longer SCs are left to differentiate in 
vitro, the lower the potential for teratoma formation following transplantation (Preynat-
Seauve et aI., 2009), differentiated cells are less stable and more difficult to manipulate. 
Noteworthy, recent investigations reveal a significant level of overlap in gene expression 
between hESC- and hiPSC-derived cells and cancer cells, suggesting that pluripotent SC-
derived cells may possess oncogenic potential even after differentiation (Ghosh et aI., 
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2011).Therefore, carrying out studies to fully understand tumor-formation pathways and 
identify compounds that can inhibit these pathways would prove valuable. 
sc DA precursor DAneuron 
Figure 7. Elimination of all pluripotent <;tem cells (follo\-\lI1g differentiation) through the use of 
fluorescence-activated cell sorting or by inducing . elective ap()pt(l~is must be carried out before 
transplantation in PO patients to avoid the formation of teratoma~ . (SC: stem cell. OA: dopaminergic) 
As mentioned earlier, the brain microenvironment plays a major role in the pathology of 
endogenous and transplanted neurons. The microenvironment that initially led to PD-
associated neuronal death may also promote degeneration of the transplanted cells. 
Recent investigations on patients with grafted fetal ventral mesencephalon showed that 
transplanted cells were affected by the brain surrounding microenvironment. In fact, 
pathological features typically seen in degenerating dopaminergic neurons in PD were 
also observed in grafted neurons (Kordower et aI., 2008; Li et aI., 2008). While a 
definitive understanding of the exact role of surrounding stroma in neurodegeneration is 
still lacking, a study by Redmond et aI. suggests that the reciprocal relationship between 
transplanted NSCs, that express neuroprotective factors, and the pathological 
microenvironment, is responsible for the functional improvement observed in primate 
models of PD. The authors implanted undifferentiated NSCs into the brains of MPTP-
treated primates and found that while only a few of the transplanted NSCs differentiated 
into tyrosine hydroxylase-positive dopaminergic neurons, the vast majority of the SCs 
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became growth factor-secreting astrocytes in the vicinity of the developing dopaminergic 
neurons (Redmond et aI., 2007). These observations led to the conclusion that astrocytes 
secrete neurotrophic, angiogenic and anti-inflammatory factors that alter the toxic 
microenvironment in the damaged areas of the brain, thereby improving the parkinsonian 
symptoms. Consistent with these findings, NSCs have been shown to constitutively 
secrete specific neurotrophic factors that promote regeneration following spinal cord 
injury (Lu et aI., 2003). Thus, the field of SC therapy should focus not only on replacing 
the dopaminergic neurons, but also on protecting the remaining endogenous neurons by 
altering the surrounding brain microenvironment. 
Transplant preparation should contain enough dopaminergic progenitors and/or midbrain 
A9 dopaminergic neurons that would survive, communicate properly with the other 
neuronal circuits in the brain, and induce marked therapeutic effect for at least several 
months after surgery, to justify such an invasive SC-based therapy in the treatment of PD. 
Maintaining the right dopamine physiological levels in the basal ganglia is crucial since 
lower or higher concentrations will result in undesirable hypo- or hyper-kinetic 
manifestations. The possibility that SCs derived from PD patients may generate 
pathological neurons due to inherent genetic abnormalities (Park et aI., 2008b) poses 
another major impediment for SC-based therapy. Furthermore, SC-derived preparations 
are permanently placed in the brain making it difficult to reverse the therapy in case the 
treatment resulted in serious adverse effects. The fact that other non-dopaminergic 
neurons such as the noradrenergic neurons of the locus coeruleus and the serotonergic 
neurons of the raphe nucleus could also degenerate particularly in the advanced stages of 
PD, further complicates cell-based therapy (Ahlskog, 2007). 
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Novel animal models and novel assessments of functional recovery should be designed to 
better reflect the different stages of the disease and the degree of recovery after cell 
replacement therapy. Typically, 6-0HDA treatment is thought to induce neuronal toxicity 
on monoamine-secreting neurons of the brain creating a somewhat reliable murine model 
of PD (Przedborski et ai., 1995; Ungerstedt, 1968). On the other hand, non-human 
primate models of PD are typically induced by injecting MPTP (Eslamboli et ai., 2005; 
Muramatsu et ai., 2009; Takagi et ai., 2005). However, these chemically-induced PD 
models are not progressive in nature and are not associated with the formation of 
proteinaceous Lewy bodies as observed in human PD, raising doubts about the reliability 
of these models. Development of genetic and/or slowly progressive animal models of PD 
will offer more robust and credible simulation of the disease that can be exploited to 
further understand the pathophysiology of the disease and identify novel therapeutic 
approaches (Litvan et ai., 2007a). 
Several questions remain to be addressed regarding the conditions and mode of delivery 
of SC-derived implants. For instance, how many cells should be transplanted? Is it better 
to inject SC-derived cells in the SNpc or the striatum or both? The two main plausible 
sites of injection are the SNpc and the corpus striatum. Intrastriatal implantation of SC 
preparations was adopted mostly because this is where the physiological dopamine is 
secreted. In addition, earlier fetal mesencephalic grafting studies in PD patients had 
adopted the intrastriatal rather than the intranigral placement of grafts. However, some 
studies have stated that intranigral injection resembles more closely the normal 
physiological state and thus it is superior to intrastriatal placement, provided that the 
resulting dopaminergic neurons would be able to extend axons to the striatum and 
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integrate properly with adjacent tissues (Preynat-Seauve et al., 2009). The main factors 
affecting the outcome of SC-based therapy in PD are shown in figure 8. 
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Figure 8. Faclor~ inlluencing the outcome or slem cell-hased replacemenl therapy in PD. 
There is still much work to do regarding the design of clinical studies in terms of patient 
selection: whether these experiments should be carried out on early-, middle- or late-
staged patients, and whether safety and/or efficacy are to be evaluated. Noteworthy, the 
possibility that transplanted SC-derived cells may dedifferentiate or migrate to 
unintended areas of the brain, which may affect patients ' mental cognition, poses an 
enormous ethical obstacle in warranting clinical trials. Therefore, SC-based therapy is 
still largely an experimental approach with MSCs being the only type of SCs to have 
been analyzed in a small-sized open-label clinical trial. Finally, a recent report goes 
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beyond the aforementioned concerns and limitations to suggest that the functional 
improvements observed in cell replacement therapy-treated PD patients are attributed to 
the surgery and/or the psychological effects associated rather than to the transplanted SC-
derived preparations. In 2000, six PD patients enrolled in a Titan Pharmaceuticals-
designed phase I clinical trial, known as Spheramine, in which cultured human retinal 
epithelial cells were implanted into the brain. A year later, the patients showed a 48% 
improvement in motor function that largely lasted for 4 years. Later on, investigators 
found out that Spheramine was no more effective than placebo, suggesting that the brain 
surgery rather than the transplanted dopamine-secreting cells was responsible for the 
reported motor improvement and indicating a potential therapeutic role for sham brain 
surgery in the treatment of PD (Katsnelson, 2011). 
Consistent with that, the placebo effect plays a prominent role in the functional 
improvements observed in treated PD patients through a reward-expectation mechanism 
which apparently results in dopamine release into the striatum (de la Fuente-Fernandez 
and Stoessl, 2002). In fact, the placebo group and the dopamine agonist (pergolide) -
treated group showed similar functional improvement (23% and 30% after 24 weeks 
respectively) (Diamond et aI., 1985). Further, several articles reviewed by Shetty et al 
reported a functional improvement following placebo treatment in PD patients, ranging 
from -10 to -60% of that seen in the drug-treated group (Shetty et aI., 1999). 
Interestingly, during a six-month study, 16% of PD subjects improved markedly on 
placebo-treatment, exhibiting 50% improvement or scoring a change in at least two motor 
items by ~ 2, based on the UPDRS (Goetz et aI., 2000). On the other hand, it is 
conceivable that the therapeutic efficacy of cell-based preparations in PD goes beyond 
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mere psychological effect smce their use in clinical trials were accompanied with 
improvements in 18F_dopa uptake (an indicator of levo-dopa intake by dopaminergic 
neurons), profuse dopaminergic neuron re-innervation, and formation of functional 
synapses in the host striatum (Hagell and Brundin, 2001). 
In summary, although SC-based cell replacement therapy is enticing in PD as it offers a 
replacement for dead neurons and a neuroprotection for the remaining functional ones, 
several obstacles hinder its clinical application in patients. Of all investigated 
impediments early senescence and the potential tumorigenicity of transplanted cells pose 
major challenges for the application of cell-based therapy. Moreover, the required good 
manufacturing practice (GMP) standards during the preparation and transplantation of the 
transplants in addition to the technical and practical issues associated with the application 
of such a sophisticated approach in an extremely sensitive organ (the brain) pose major 
challenges. Hence, it is obvious that SC-based therapy for PD is still at an early stage 
and that more investigations are needed to resolve the associated safety, efficacy and 
technical concerns. 
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CHAPTER V 
CONCLUSION 
PD presents a major challenge because none of the existing therapies are capable of 
halting and/or reversing the progressive neurodegeneration. Newer approaches involving 
neurotrophic factors, gene therapy and SCs are advantageous and must be further 
developed since they offer a modifying potential to PD pathophysiology, either by 
replacing and/or protecting dopaminergic neurons. Among the newer approaches, only 
SC-based therapies actually provide a replacement for lost dopaminergic neurons in PD. 
It is encouraging that this relatively new field is advancing fast, achieving significant 
results in animal models of PD, albeit with a few unresolved concerns. Among these 
concerns, ethical issues, poor survivability of transplants and the inherent tumorigenicity 
of pluripotent SCs hinder further advancement of the field. It is thus imperative that 
intense investigations be carried out to circumvent tumorigenicity and prolong 
survivability. Placebo-controlled double-blind clinical trials should then be initiated in 
patients to establish the safety and efficacy of SC-based anti-PD therapies. Success of 
SC-based preparations will have implications not only in PD but also in other 
neurodegenerative diseases including Alzheimer's disease. Hence it is conceivable that 
once the current impediments facing SC-based cell replacement therapy are resolved, it 
will emerge as an efficacious treatment of choice in combating PD. 
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